Pharma BD Deal Intelligence

CSPC Pharmaceutical Group Ltd. / AstraZeneca PLC

2026 · Co-Development · Pending

CSPC Pharmaceutical and AstraZeneca agreed to form a 51:49 joint venture (CSPC majority) to build and operate a biologics manufacturing facility in Shijiazhuang, China. The venture will initially produce mutually agreed biologics drug substances for global markets, combining CSPC's AI-driven GMP platform and manufacturing execution with AstraZeneca's global quality standards and supply chain management, with scope to add further products. Financial terms were not disclosed. The joint venture contract remains subject to closing conditions including regulatory approvals before construction can proceed. It follows prior CSPC-AstraZeneca agreements, including a 2025 AI-enabled preclinical oral discovery collaboration and a 2026 obesity/type 2 diabetes partnership.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals